Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Levocarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CPT2 | P23786 | 2/20 | 0.55 |
| ▸ | CPT1A | P50416 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | CRAT | P43155 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carnitine SCHEMBL867251 | 1.00 | SLC22A16 (0.87) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL28744379 | 0.98 | SLC22A16 (0.83) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL29036059 | 0.93 | SLC22A16 (0.91) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL1813524 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL21971 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Levocarnitine SCHEMBL21970 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| D-Carnitine SCHEMBL94286 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL3902633 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL17629811 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Levocarnitine SCHEMBL4593172 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257221-B2 | Leucine-enriched ketogenic formulations | AJINOMOTO CO., INC. (JP) | 2025-03-25 | — | — | US | disclosed |
| CN-113646014-A | Antioxidant-releasing vitreous substitute and use thereof | 俄亥俄州创新基金会 | 2021-11-12 | — | — | CN | disclosed |
| US-20210205252-A1 | LEUCINE-ENRICHED KETOGENIC FORMULATIONS | AJINOMOTO CO., INC. (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20180110241-A1 | AQUEOUS KETOGENIC COMPOSITIONS | Cambrooke Therapeutics, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3273804-A1 | AQUEOUS KETOGENIC COMPOSITIONS | Cambrooke Therapeutics, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016154575-A1 | AQUEOUS KETOGENIC COMPOSITIONS | Cambrooke Therapeutics, Inc. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-9289428-B2 | Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer | RAMSCOR, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140329785-A1 | Conveniently Injectable or Implantable Sustained-Release Antioxidant Formulations for Therapies of Ocular Maladies or Cancer | RAMSCOR, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20020106388-A1 | Formulation of flavones and isoflavones for treatment of cellulite | PUGLIESE PETER T (US) | 2002-08-08 | — | — | US | disclosed |